China Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Buy Report

Published: June 23, 2025 Report Code: GDME25617CCDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “China Oncology Market Outlook to 2033” is a comprehensive databook report, covering key market data on the China Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The China Oncology Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for Oncology Market.
• Global corporate-level profiles of key companies operating within the China Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

China Oncology is segmented as follows – _x000D_

• Colorectal Cancer Screening Tests_x000D_

• EGFR Tests_x000D_

• KRAS Tests_x000D_

• HER2 Tests_x000D_

• BRCA Tests_x000D_

• ALK Tests_x000D_

• BRAF Tests_x000D_

• BCR-ABL Tests_x000D_

• PD-L1 Tests

Reasons to Buy

The China Oncology Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Abbott Laboratories

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 5

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Oncology Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 9

3 Oncology Market, China 16

3.1 Oncology Market, China, Revenue ($m), 2018-2033 16

3.1.1 ALK Tests Market, China, Revenue ($m), by Segment, 2018-2033 19

3.1.2 BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), by Segment, 2018-2033 21

3.1.3 BRAF Tests Market, China, Revenue ($m), by Segment, 2018-2033 23

3.1.4 BRCA Tests Market, China, Revenue ($m), by Segment, 2018-2033 25

3.1.5 Colorectal Cancer Screening Tests Market, China, Revenue ($m), by Segment, 2018-2033 27

3.1.6 EGFR Tests Market, China, Revenue ($m), by Segment, 2018-2033 29

3.1.7 HER2 Tests Market, China, Revenue ($m), by Segment, 2018-2033 31

3.1.8 KRAS Tests Market, China, Revenue ($m), by Segment, 2018-2033 33

3.2 Oncology Market, China, Volume (Units), 2018-2033 35

3.2.1 ALK Tests Market, China, Volume (Units), by Segment, 2018-2033 38

3.2.2 BCR-ABL Tests Market, China, Volume (Units), by Segment, 2018-2033 40

3.2.3 BRAF Tests Market, China, Volume (Units), by Segment, 2018-2033 42

3.2.4 BRCA Tests Market, China, Volume (Units), by Segment, 2018-2033 44

3.2.5 Colorectal Cancer Screening Tests Market, China, Volume (Units), by Segment, 2018-2033 46

3.2.6 EGFR Tests Market, China, Volume (Units), by Segment, 2018-2033 48

3.2.7 HER2 Tests Market, China, Volume (Units), by Segment, 2018-2033 50

3.2.8 KRAS Tests Market, China, Volume (Units), by Segment, 2018-2033 52

3.3 Oncology Market, China, Average Price ($) , 2018-2033 54

3.4 Oncology Market, China, Company Share by Revenue ($m), 2024 57

4 Overview of Key Companies in China, Oncology Market 59

4.1 F. Hoffmann-La Roche Ltd 59

4.1.1 Company Overview 59

4.2 BioGenex Laboratories Inc 59

4.2.1 Company Overview 59

4.3 Amoy Diagnostics Co Ltd 59

4.3.1 Company Overview 59

4.4 Abbott Laboratories 59

4.4.1 Company Overview 59

4.5 Danaher Corp 60

4.5.1 Company Overview 60

4.6 Eiken Chemical Co Ltd 60

4.6.1 Company Overview 60

4.7 Agilent Technologies Inc 60

4.7.1 Company Overview 60

4.8 Hemosure Inc 60

4.8.1 Company Overview 60

4.9 Alfresa Pharma Corp 60

4.9.1 Company Overview 60

4.10 SENTINEL CH SpA 61

4.10.1 Company Overview 61

5 Oncology Market Pipeline Products 62

6 Financial Deals Landscape 127

6.1 Equity Offerings 127

6.1.1 Pheton Holdings (Beijing Feitian Zhaoye Technology) Raises USD9 Million in Initial Public Offering (IPO) of Shares 127

6.1.2 Elpiscience Biopharma to Raise Funds through Initial Public Offering (IPO) of Shares 129

6.2 Partnerships 130

6.2.1 Guangzhou Concord Cancer Center Enters into Licensing Agreement for Proton Therapy Equipment 130

6.3 Venture Financing 131

6.3.1 Suzhou Linaxin Biotechnology (Linaxin) Secures Series A Funding 131

6.3.2 Shanghai Tongshu Biological Technology (Changzhou Tongshu Biological Technology, Tongshu Gene, Tung Tree Gene) Raises Approximately USD14.15 Million in Series D Financing 132

6.3.3 Jiangsu Xunyuan Biotech Raises More than USD13.75 Million in Venture Financing 133

6.3.4 Shenyang Neusoft Zhirui Radiotherapy Technology (Neusoft Zhirui) Raises Approximately USD13.77 Million in Series C Financing 134

7 Recent Developments 135

7.1 Other Significant Developments 135

7.1.1 Mar 03, 2025: TruScreen – Key Markets Update and Revenue Guidance 135

7.1.2 Sep 12, 2024: BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions 136

7.2 Product News 137

7.2.1 May 29, 2025: Concord Healthcare Announces Official Release of the Proton Therapy Large Model 137

7.2.2 Apr 27, 2025: The Group’s Early Detection Product for Urinary System Tumors Achieves Its First Commercial Prescription in Mainland China 137

7.2.3 Feb 16, 2025: HKU Team Develops AI-Driven Tool to Accelerate Cancer Diagnosis 138

7.2.4 Feb 14, 2025: New Patent Approval in China Strengthens the AroCell Patent Portfolio 139

7.2.5 Jan 15, 2025: CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology 140

7.2.6 Nov 11, 2024: Report Published by Research Journal, Germany’s Springer Concluded that TruScreen Cervical Cancer Screening Results were Comparable and Better than conventional LBC 140

7.2.7 Sep 20, 2024: Researchers Use Cholesterol-Enriched Exosomes to Improve Sirna Delivery 141

7.2.8 Sep 16, 2024: Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment 142

7.2.9 Aug 23, 2024: Breakthroughs in Prostate Cancer: New Insights into Biomarkers and Probes 142

7.3 Strategy And Business Planning 143

7.3.1 Sep 12, 2024: BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions 143

7.3.2 Jul 11, 2024: MGI Announces Collaboration With Predica Diagnostics 144

7.3.3 Jun 28, 2024: Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China 145

8 Appendix 147

8.1 Research Methodology 148

8.1.1 Coverage 148

8.1.2 Secondary Research 148

8.1.3 Primary Research 148

8.1.4 Market Modeling and Forecasting 149

8.1.5 Company Share Analysis 150

8.1.6 Benchmarking 151

8.2 GlobalData Consulting 152

8.3 Contact Us 152

8.4 Disclaimer 152

Table

Table 1: Oncology Market, China, Revenue ($m), USD Constant, 2018-2033 17

Table 2: ALK Tests Market, China, Revenue ($m), USD Constant, 2018-2033 20

Table 3: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), USD Constant, 2018-2033 22

Table 4: BRAF Tests Market, China, Revenue ($m), USD Constant, 2018-2033 24

Table 5: BRCA Tests Market, China, Revenue ($m), USD Constant, 2018-2033 26

Table 6: Colorectal Cancer Screening Tests Market, China, Revenue ($m), USD Constant, 2018-2033 28

Table 7: EGFR Tests Market, China, Revenue ($m), USD Constant, 2018-2033 30

Table 8: HER2 Tests Market, China, Revenue ($m), USD Constant, 2018-2033 32

Table 9: KRAS Tests Market, China, Revenue ($m), USD Constant, 2018-2033 34

Table 10: Oncology Market, China, Volume (Units), 2018-2033 36

Table 11: ALK Tests Market, China, Volume (Units), 2018-2033 39

Table 12: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Volume (Units), 2018-2033 41

Table 13: BRAF Tests Market, China, Volume (Units), 2018-2033 43

Table 14: BRCA Tests Market, China, Volume (Units), 2018-2033 45

Table 15: Colorectal Cancer Screening Tests Market, China, Volume (Units), 2018-2033 47

Table 16: EGFR Tests Market, China, Volume (Units), 2018-2033 49

Table 17: HER2 Tests Market, China, Volume (Units), 2018-2033 51

Table 18: KRAS Tests Market, China, Volume (Units), 2018-2033 53

Table 19: Oncology Market, China, Average Price ($), 2018-2033 54

Table 19: Oncology Market, China, Company Share by Revenue ($m), 2024 58

Table 20: Oncology Market Pipeline Products 62

Table 21: Pheton Holdings (Beijing Feitian Zhaoye Technology) Raises USD9 Million in Initial Public Offering (IPO) of Shares 127

Table 22: Elpiscience Biopharma to Raise Funds through Initial Public Offering (IPO) of Shares 129

Table 23: Guangzhou Concord Cancer Center Enters into Licensing Agreement for Proton Therapy Equipment 130

Table 24: Suzhou Linaxin Biotechnology (Linaxin) Secures Series A Funding 131

Table 25: Shanghai Tongshu Biological Technology (Changzhou Tongshu Biological Technology, Tongshu Gene, Tung Tree Gene) Raises Approximately USD14.15 Million in Series D Financing 132

Table 26: Jiangsu Xunyuan Biotech Raises More than USD13.75 Million in Venture Financing 133

Table 27: Shenyang Neusoft Zhirui Radiotherapy Technology (Neusoft Zhirui) Raises Approximately USD13.77 Million in Series C Financing 134

Table 28: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 149

Figures

Figure 1: Oncology Market, China, Revenue ($m), USD Constant, 2018-2033 16

Figure 2: ALK Tests Market, China, Revenue ($m), USD Constant, 2018-2033 19

Figure 3: BCR-ABL Nucleic Acid Amplification Tests (NAATs) Market, China, Revenue ($m), USD Constant, 2018-2033 21

Figure 4: BRAF Tests Market, China, Revenue ($m), USD Constant, 2018-2033 23

Figure 5: BRCA Tests Market, China, Revenue ($m), USD Constant, 2018-2033 25

Figure 6: Colorectal Cancer Screening Tests Market, China, Revenue ($m), USD Constant, 2018-2033 27

Figure 7: EGFR Tests Market, China, Revenue ($m), USD Constant, 2018-2033 29

Figure 8: HER2 Tests Market, China, Revenue ($m), USD Constant, 2018-2033 31

Figure 9: KRAS Tests Market, China, Revenue ($m), USD Constant, 2018-2033 33

Figure 10: Oncology Market, China, Volume (Units), 2018-2033 35

Figure 11: ALK Tests Market, China, Volume (Units), 2018-2033 38

Figure 12: BCR-ABL Tests Market, China, Volume (Units), 2018-2033 40

Figure 13: BRAF Tests Market, China, Volume (Units), 2018-2033 42

Figure 14: BRCA Tests Market, China, Volume (Units), 2018-2033 44

Figure 15: Colorectal Cancer Screening Tests Market, China, Volume (Units), 2018-2033 46

Figure 16: EGFR Tests Market, China, Volume (Units), 2018-2033 48

Figure 17: HER2 Tests Market, China, Volume (Units), 2018-2033 50

Figure 18: KRAS Tests Market, China, Volume (Units), 2018-2033 52

Figure 19: Oncology Market, China, Company Share (%), 2024 57

China Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others standard reports

Currency USD

Single User

$4,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Global M&A Deals in H1 2026 - Top Themes by…

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at China Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others in real time.

Access a live China Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

China Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports